Compare General Dynamics Corporation (GD) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs TransMedics Group Inc — how do they compare? General Dynamics Corporation trades at $331.27 (market cap $89.26B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: General Dynamics Corporation is far larger — about 32.6× TransMedics Group Inc's market cap, and General Dynamics Corporation pays a 1.93% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 85 Days and TransMedics Group Inc for 24 Days on average.
| GD | TMDX | |
|---|---|---|
Market Cap | $89.26B | $2.74B |
Volume | 1,496,273 | 949,331 |
Sector | Industrials | Health |
52-Week High | $395.97 | $150.42 |
52-Week Low | $312.53 | $61.99 |
Typical Hold Time | 85 Days | 24 Days |
Enterprise Value | $94.40B | $3.13B |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $329.90, up 1.0% with strong fundamental performance including three consecutive quarterly earnings beats and robust 2025 revenue of $52.55 billion. The stock shows bearish technical signals despite positive analyst sentiment with a $420.57 consensus price target representing 27.5% upside potential. Defense sector tailwinds from Pentagon spending and dividend stability support the investment case.
GD presents a compelling value opportunity with reasonable valuation multiples (P/E 20.12, P/S 1.65) and strong profitability metrics (ROE 17.8%, net margin 8.18%). Key risks include defense budget volatility and technical weakness, but the company's consistent earnings performance and analyst support suggest potential for medium-term appreciation.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
